The company provides financial advisory and consulting services, including debt structuring and project appraisals, while also maintaining licenses for stock brokerage and wealth management. It earns revenue primarily through service fees and consulting charges for corporate and commercial financial matters.
The company possesses no identifiable competitive advantage, as evidenced by its extremely small revenue base and history of significant losses. While it holds technical know-how for a medical device (vestibulator), it recently transferred this asset to a related party for no cash consideration, effectively stripping the entity of its primary intellectual property.
Capital allocation has been value-destructive; the company has historically generated negative returns on equity and recently offloaded its main intangible assets to a related party to settle liabilities rather than generating cash. Reinvestment in the core business has failed to produce meaningful top-line growth or profitability.
The company's demise was preordained when it hollowed itself out by transferring its primary intellectual property to a related party for zero cash. Deprived of its only meaningful asset, the entity became a shell that continued to burn through related-party loans to fund administrative overhead. The lack of a viable revenue engine, combined with the loss of technical know-how, eventually led to a total collapse in shareholder value as the 'ACME' rebranding failed to mask the absence of a functional business model.
RichFakir rates Transpact Enterprises Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Transpact Enterprises Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Transpact Enterprises Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Transpact Enterprises Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →